News

The Pharma Letter18m
Novo Nordisk expands legal action on non-FDA-approved compounded "semaglutide"
Danish diabetes and obesity giant Novo Nordisk has announced the filing of 14 new lawsuits to safeguard patients from unsafe ...
Pharmaceutical Technology58m
Novo Nordisk’s diabetes and weight loss drug sales growth decelerates
H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.